Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/31/2026

1. INTC
2. AMZN
3. RDDT
4. PINS
5. COIN
6. FSLR
7. SYK
8. MA
9. FND
10. DASH

Go back to Arbutus Biopharma (ABUS) Misses Q1 EPS by 8c

Arbutus Reports First Quarter 2019 Financial Results and Provides Corporate Update

May 6, 2019 4:01 PM EDT


Top-line safety and efficacy results from an interim analysis of the initial Phase 1a/1b clinical trial of AB-506, a proprietary oral capsid inhibitor, expected in July 2019

Conference Call and Webcast Scheduled Today at 4:30 PM ET

WARMINSTER, Pa., May 06, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today reports its first quarter 2019... More